Radical prostatectomy for locally advanced and high-risk prostate cancer: A systematic review of the literature
被引:13
|
作者:
Delporte, G.
论文数: 0引用数: 0
h-index: 0
机构:
CHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, FranceCHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, France
Delporte, G.
[1
]
Henon, F.
论文数: 0引用数: 0
h-index: 0
机构:
CHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, FranceCHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, France
Henon, F.
[1
]
Ploussard, G.
论文数: 0引用数: 0
h-index: 0
机构:
Inst Univ Canc Toulouse, F-31100 Toulouse, France
St Jean Languedoc Hosp, Dept Urol, F-31400 Toulouse, FranceCHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, France
Ploussard, G.
[2
,3
]
Briganti, A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Vita Salute San Raffaele, Dept Urol, Milan, ItalyCHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, France
Briganti, A.
[4
]
Rizk, J.
论文数: 0引用数: 0
h-index: 0
机构:
CHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, FranceCHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, France
Rizk, J.
[1
]
Rozet, F.
论文数: 0引用数: 0
h-index: 0
机构:CHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, France
Rozet, F.
Touijer, K.
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USACHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, France
Touijer, K.
[5
]
Ouzzane, A.
论文数: 0引用数: 0
h-index: 0
机构:
CHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, FranceCHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, France
Ouzzane, A.
[1
]
机构:
[1] CHRU Lille, Hop Claude Huriez, Dept Urol, F-59037 Lille, France
[2] Inst Univ Canc Toulouse, F-31100 Toulouse, France
[3] St Jean Languedoc Hosp, Dept Urol, F-31400 Toulouse, France
[4] Univ Vita Salute San Raffaele, Dept Urol, Milan, Italy
[5] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA
Context. - The role of radical prostatectomy (RP) in high-risk prostate cancer (PCa) is increasing. Purpose. - To review the existing literature and determine the value of RP in high-risk and locally advanced PCa. Documentary source. - MEDLINE, Embase and the Cochrane Central Register of Controlled Trials were searched from 01/2000 through 05/2016 according to the PRISMA guidelines. Selection of studies. - Forty-two studies describing outcomes of RP among 52,546 patients with high-risk and locally advanced PCa. Results. - Mortality was approximately 0-1% and Clavien >= 3 complications ranged from 1.8% to 12%. Biochemical recurrence-free and metastasis-free survival ranged from 40 to 94% and 90 to 96.1% at 5 years and from 27 to 68% and 64.4 to 85.1% at 10 years, respectively. Overall and cancer specific survival ranged from 55.2 to 98.6% and 89.8 to 100% at 5 years and from 58 to 84% and 65 to 96% at 10 years, respectively. The 12-mo continence rates ranged from 32% to 96.2% and the erectile function recovery ranged from 60% to 64%. Limits. - Studies were heterogeneous especially regarding the definition of high-risk disease and the use of adjuvant treatments. Conclusions. - The utilization of RP in high-risk and locally advanced PCa is increasing. Existing data support the advantages of RP in this group of patients. However, uniformity in definitions and indications are a prerequisite in order to establish its role as an important therapeutic arm in a multimodality management strategy. (C) 2018 Elsevier Masson SAS. All rights reserved.
机构:
Department of Uro-Oncology, HCG Bangalore Institute of Oncology, BangaloreDepartment of Uro-Oncology, HCG Bangalore Institute of Oncology, Bangalore
Srivatsa N.
Nagaraja H.
论文数: 0引用数: 0
h-index: 0
机构:
Department of Uro-Oncology, HCG Bangalore Institute of Oncology, BangaloreDepartment of Uro-Oncology, HCG Bangalore Institute of Oncology, Bangalore
Nagaraja H.
Shweta S.
论文数: 0引用数: 0
h-index: 0
机构:
Department of Uro-Oncology, HCG Bangalore Institute of Oncology, BangaloreDepartment of Uro-Oncology, HCG Bangalore Institute of Oncology, Bangalore
Shweta S.
Raghunath S.
论文数: 0引用数: 0
h-index: 0
机构:
Department of Uro-Oncology, HCG Bangalore Institute of Oncology, BangaloreDepartment of Uro-Oncology, HCG Bangalore Institute of Oncology, Bangalore
机构:
Rabin Med Ctr, Dept Urol, IL-49726 Petah Tiqwa, IsraelMem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA
Yossepowitch, Ofer
Eastham, James A.
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USAMem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA